Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,906.31 +1,501.79 (+2.30%) CMC Crypto 200
1,369.64 -4.20 (-0.31%)
PTCT May 2024 29.000 call
| Previous close | 3.5000 |
| Open | 1.2500 |
| Bid | 3.4000 |
| Ask | 6.5000 |
| Strike | 29.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.2500 - 3.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
PR NewswirePTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the FDA has accepted for filing the Biologics License Application (BLA) for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of AADC deficiency. The application has been granted Priority Review with a target regulatory action date of November 13, 2024.
PR NewswirePTC Therapeutics to Participate at Upcoming Investor Conferences
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conferences:
Insider MonkeyPTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript April 25, 2024 PTC Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.2, expectations were $-1.31. PTC Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank […]
